Multiple Law Firms Seek Lead Plaintiffs in Erasca Securities Suit Ahead of August 10 Deadline

Overview

• The notices were issued on August 3, 2026 by several plaintiff firms reminding investors of an August 10 deadline to seek appointment as lead plaintiff in securities suits against Erasca.
• The complaints allege Erasca made false or misleading public statements about ERAS-0015, including an improper preclinical comparison with Revolution Medicines that created patent and trade‑secret exposure.
• Those suits say the market learned the alleged truth after disclosures about a Revolution Medicines letter and adverse Phase 1 safety data, and that investors who bought ERAS stock during the class period suffered losses.
• All filings remain un‑certified so potential class members are not represented by counsel until certification, and the firms’ notices are identified as attorney advertising under ethics rules.
• A lead plaintiff chosen after the August 10 motions would direct the litigation and shape discovery into patent, trade‑secret and safety issues, which will affect how claims are pursued and the timeline for any recovery.